Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 93, Issue 1, Pages 223-233Publisher
WILEY
DOI: 10.1002/jmv.26197
Keywords
COVID-19; hematological diseases; SARS-CoV-2
Categories
Ask authors/readers for more resources
SARS-CoV-2 is a disease caused by a recently emerged virus, with most cases having a mild course but posing a higher risk to the elderly and individuals with comorbidities. There is currently no specific vaccine, and treatment strategies involve antiviral medications and drugs to moderate cytokine storms.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a disease known from a few months, caused by a recently arisen virus and, consequently, it is little known. The disease has a benign course in most infected subjects (children and young adults), is often symptomatic in adults over the age of 50 and often serious and life threatening in people with comorbidities and the elderly. The few data published on coronavirus disease-2019 (COVID-19) in the blood-oncology field report a serious clinical presentation, a serious course of the disease, and a high mortality rate, as has also been reported for other cancer contexts. The current strategy for treating patients with SARS-CoV-2 includes antivirals that are effective against other viral infections and drugs that can moderate the cytokine storm. There is no specific vaccine and consequently all possible precautions must be taken to prevent SARS-CoV-2 infection in the areas of oncology, oncohematology, and bone marrow transplantation. In this reviewer's article, we report the information currently available on SARS-CoV-2 infection to help young doctors and hematologists to successfully manage patients with COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available